INCREASING TO 6 ISSUES FROM 2010. SUBMIT ONLINE TODAY.
CNS Neuroscience & Therapeutics
Formerly CNS Drug Reviews
Edited by:
Editor in Chief: Mark H. Pollack, MD Co-Editor: Roger Bullock, Swindon, UK
Impact Factor: 4.432
CNS Neuroscience & Therapeutics (formerly CNS Drug Reviews) publishes original research papers, timely reviews and reports of novel findings of therapeutic relevance. The journal focuses on the neuroscience, phenomenology and pathophysiology, as well as pharmacologic and psychosocial therapeutics, of psychiatric and related disorders.
For informal and rapid pre-submission guidance, send your abstract and brief note explaining why your manuscript is suitable by email to the Managing Editor at rosanna.diogini@wiley.com. For tips about preparing and submitting manuscripts, automated email tracking and more, visit the Blackwell Publishing Author Services Website on http://www.blackwellpublishing.com/bauthor.
TopNews and Announcements
Frequency Increase
From 2010 CNS Neuroscience & Therapeutics will increase to 6 issues per year. Submit your paper online today.
Title change for 2008
(Please note the current Impact Factor for the journal is listed in ISI Journal Citation Reports under the previous journal name).
From 2008 the journal will be known as CNS Neuroscience & Therapeutics, offering:
- Fast online publication via Early View
- Manuscript Central electronic editorial office
- Publication of original research articles
- Freely available article content
Online Content Now Available Back to Volume 1
All back issues of this journal are available online. Click here to browse contents and abstracts. For further information on how to access these issues please visit our Librarian Site.
NIH Public Access Mandate
For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our policy statement.
TopHighlights
Following are the five most cited articles published in CNS Neuroscience & Therapeutics (formerly CNS Drug Reviews) in 2008:
Preclinical characterization of A-582941: A novel alpha 7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties
Tietje, KR; Anderson, DJ; Bitner, RS; Blomme, EA; Brackemeyer, PJ; Briggs, CA; Browman, KE; Bury, D; Curzon, P; Drescher, KU; Frost, JM; Fryer, RM; Fox, GB; Gronlien, JH; Hakerud, M; Gubbins, EJ; Halm, S; Harris, R; Helfrich, RJ; Kohlhaas, KL; Law, D; Malysz, J; Marsh, KC; Martin, RL; Meyer, MD; Molesky, AL; Nikkel, AL; Otte, S; Pan, LP; Puttfarcken, PS; Radek, RJ; Robb, HM; Spies, E; Thorin-Hagene, K; Waring, JF; Ween, H; Xu, HY; Gopalakrishnan, M; Bunnelle, WH
The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties
Kotani, Y; Shimazawa, M; Yoshimura, S; Iwama, T; Hara, H
GABA(A) receptor subtype-selective efficacy: TPA023, an alpha 2/alpha 3 selective non-sedating anxiolytic and alpha 5IA, an alpha 5 selective cognition enhancer
Atack, JR
Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate
Shank, RP; Maryanoff, BE
Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury
Lee, JH; Park, SY; Shin, HK; Kim, CD; Lee, WS; Hong, KW
